Balofloxacin and levofloxacin in the treatment of 215 cases of bacterial infections in urinary system lower respiratory tract
Abstract
Objective:To evaluate the clinical efficacy and safety of balofloxacin in the treatment of bacterial infections in urinary system. Methods:A total of Two-hundred and twenty-nine patients with respiratory infections were enrolled in this multicenter,randomized controlled clinical study.One-hundred and five patients as trial group received balofloxacin and One-hundred and ten patients as control group received levofloxacin.Both groups were given drug 0.1g twice daily,period for 5 to 14 days.Results:The cure and effective rates were 77.1%and 96.2%,respectively in balofloxacin group,81.8%and 97.3%,respectively in levofloxacin group;the bacterial culture-positive rates were in balofloxacin and levofloxacin group 78%and 77.3%,respectively;the bacterial eradication rates were 95.1%and 94.1%,respectively;the adverse events rate were 8.2%and 8.9%,respectively.There were no significant differences between the two groups(P0.05).Conclusion:Balofloxacin is as effective and well-tolerated as levofloxacin for the treatment of bacterial infections in urinary system respiratory tract.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.